Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetes Care

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.28.4.931PMID 15793200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.

  2004cited by this paper
• Preventive cardiology: abstractLp (a) lipoprotein, vascular disease and mortality in the elderly

  2004cited by this paper
• Lp(a) lipoprotein, vascular disease, and mortality in the elderly.

  2003cited by this paper
• Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.

  2002cited by this paper
• Predictors of macrovascular disease in patients with type 2 diabetes mellitus.

  2001cited by this paper
• Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.

  2001cited by this paper
• Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies

  2000cited by this paper
• Effect of Insulin Administration on Serum Lipoprotein(a) and Its Phenotypes in New-Onset IDDM Patients

  1998cited by this paper
• Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age.

  1996cited by this paper
• Prospective Study of Lipoprotein(a) as a Risk Factor for Atherosclerotic Cardiovascular Disease in Patients With Diabetes

  1995cited by this paper
• Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study.

  1993cited by this paper
• The WHO Multinational Study of Vascular Disease in Diabetes: 1. General Description

  1979cited by this paper
• The WHO Multinational Study of Vascular Disease in Diabetes: 2. Macrovascular Disease Prevalence

  1979cited by this paper

• Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis

  2023cites this paper
• Relation of Serum Lipoprotein (a) and Severity of Coronary Artery Disease in Type 2 Diabetic Patients

  2022cites this paper
• Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study.

  2020cites this paper
• Effects of Conjugated Linoleic Acid Intake in the Form of Dietary Supplement or Enriched Food on C-Reactive Protein and Lipoprotein (a) Levels in Humans: A Literature Review and Meta-Analysis

  2019cites this paper
• Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus.

  2018cites this paper
• COMPARISON OF SERUM LIPOPROTEIN (A) LEVEL IN TYPE 2 DM AND NON-DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME

  2018cites this paper
• Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People.

  2017cites this paper
• Cardiovascular risk assessment and screening in diabetes.

  2017cites this paper
• Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study

  2016influential citation
• Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.

  2016cites this paper
• Elevated Lipoprotein(a) has Incremental Prognostic Value in Type 2 Diabetic Patients with Symptomatic Coronary Artery Disease.

  2015cites this paper
• Effect of statins on lipoprotein (a) in dyslipidemic patients

  2014cites this paper
• Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

  2012cites this paper
• Genetic variants , plasma lipoprotein ( a ) levels , and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes

  2012cites this paper
• Lipoprotein(a) and cardiovascular disease in diabetic patients

  2012cites this paper
• Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial.

  2011cites this paper
• Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes.

  2011cites this paper
• Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.

  2011cites this paper
• Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)

  2010cites this paper
• Lipoprotein a: where are we now?

  2009cites this paper
• Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease

  2008cites this paper
• Lipids in Health and Disease

  2008cites this paper
• Lipoprotein(a) – Structure, Epidemiology, Function and Diagnostics of a Cardiovascular Risk Marker

  2008cites this paper
• Lipids in Health and Disease

  2008cites this paper
• Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.

  2008cites this paper
• in press-uncorrected proof Stoffwechsel Redaktion : W . März Lipoprotein ( a ) – Struktur , Epidemiologie und Funktion Lipoprotein ( a ) – structure , epidemiology and function

  2007cites this paper
• Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease

  2007cites this paper
• Current literature in diabetes

  2006cites this paper
• IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes.

  2006cites this paper
• Metabolic Profiling in Personalized Medicine: Bridging the Gap between Knowledge and Clinical Practice in Type 2 Diabetes Identifying Asymptomatic Subjects at Risk of Developing Dm2 Predictors of Cardiovascular Complications in Dm2 Patients Conclusion & Future Perspective

  year unknowncites this paper